Why Corcept Therapeutics Incorporated Stock Is Getting Clobbered Today

MarketsMotley Fool

What happened

Corcept Therapeutics (NASDAQ: CORT), an endocrine-oriented drugmaker, is having an exceptionally bad day today. The drugmaker's shares are in free fall, thanks to Teva Pharmaceutical Industries' (NYSE: TEVA) decision to file a U.S. marketing application for a generic version of the company's only marketed drug, Korlym, indicated for patients suffering from Cushing syndrome.

Continue Reading Below

In response to this news, Corcept's shares were down by 24.6% on over three times the average daily volume at 2:15 p.m. EST. Teva's shares, on the other hand, are failing to respond to this positive regulatory development. The Israeli generic-drug giant's shares are down by 1.8% at this writing, and are largely sinking in lockstep with the broader markets today.

So what

Teva is arguing that either its generic product won't infringe on Korlym's patents, or the branded drug's key patents are "invalid and/or are unenforceable." Not surprisingly, Corcept's management isn't buying this kitchen-sink argument, with the company set to "vigorously defend" Korlym's intellectual property.

Now what

As a patent dispute can take several years to resolve, the market appears to be overreacting to this particular piece of news. In other words, Teva could end up winning this patent dispute, but it won't happen anytime soon.

That being said, Corcept's shares have been trading at a sky-high premium for a while now, so a healthy pullback was likely coming down the pike anyways.

In all, this sizable downturn might actually represent an attractive entry point for risk-tolerant investors. Corcept, after all, should be able to successfully fend off Teva's patent challenge to continue generating industry-leading levels of top-line growth.

10 stocks we like better than Corcept TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Corcept Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 5, 2018

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Continue Reading Below